Teva settles DOJ price-fixing charges with $225M fine, DPA; avoids federal exclusion

TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva enters Deferred Prosecution Agreement with DOJ over 2020 price-fixing charges for generic drugs.
Fine of $225M payable over 5 years: $22.5M/yr 2024-2027, $135M in 2028.
Teva to donate $50M of two generic products (at wholesale cost) and divest one generic product.
Admits a single former employee engaged in three instances of collusion with competitors (2013-2015).
DPA term is 3 years; upon compliance and payment, charges dismissed with prejudice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.